New drug TESP-0401 enters first human safety tests

NCT ID NCT07658638

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study tests the safety of a new drug, TESP-0401, in 68 healthy volunteers. Participants receive either the drug or a placebo as a single dose or daily for 7 days. Researchers will monitor side effects and measure how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TESP-0401

What could go wrong

This is an early phase 1 study in healthy people, so it only tests safety and drug processing—not whether it works for any disease. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Novatrials

    Charlestown, Suite 301, 99 Pacific Highway,NSW, 2290, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••